Howard S Hochster, MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

  • Esophageal Neoplasms
  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Colorectal Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Gastrointestinal Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Clinical Trials

Conditions Study Title
Other Digestive Organ, Pancreas E2211: Phase II study of Temozolomide or Temozolomide + Capecitabine in Patients w Pancreatic Tumors
Pancreas Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Pancreas Phase II Gemcitabine & Nab-paclitaxel +/- NPC-1C in metastatic or locally advanced pancreatic cancer
Other Digestive Organ Phase Ib study of DKN-01 plus gemcitabine and cisplatin in pts biliary system or gallbladder cancer
Other Digestive Organ, Stomach Phase 3 study of Ramucirumab in combination with Capecitabine & Cisplatin in pts with stomach cancer
Breast - Female, Breast - Male, Lung, Pancreas Nivolumab in combination with nab-paclitaxel based therapy in Panc, NSCLC, and mBC
Pancreas Olaparib in gBRCA Mutated Pancreatic Cancer pts Not Progressed on 1st Line Platinum-Based Chemo
Esophagus, Other Digestive Organ Phase 1 study of DKN-01 plus Paclitaxel in pts with relapsed or refractory esophageal or GEJ cancer
Colon, Rectum Phase III study of Nintedanib plus BSC vs placebo plus BSC in pts with refractory colorectal cancer
Colon Pilot Study of Xolair in Reducing Oxaliplatin-induced HSR
Colon, Rectum S1406: Phase II study of irinotecan and cetuximab +/- vemurafenib in BRAF mutant metastatic CRC
Pancreas nab-paclitaxel plus gemcitabine in subjects with locally advanced pancreatic cancer
Pancreas Phase 3 study of adjuvant nab-Paclitaxel + gemcitabine vs. gemcitabine in resected pancreatic cancer
Pancreas S1313: Phase Ib/II Study of mFOLFIRINOX +PEGPH20 vs. mFOLFIRINOX in Met. Pancreatic Adenocarcinoma
Colon S0820: Preventing Adenomas of the Colon with Eflornithine and Sulindac
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Breast - Female, Lung, Ovary, Pancreas, Stomach Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors
Pancreas Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Colon E7208: Phase II: Irinotecan and Cetuximab +/- Ramucirumab K-ras Wild-Type Colon Cancer
Esophagus RTOG 1010: Phase III Trastuzumab + Trimodality Treat of HER2-Overexpress'g Esophageal Adenocarcinoma

Edit this profile

Contact Info

Howard S Hochster, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
View on map...
Mailing Address
333 Cedar Street
Box 208028

New Haven, CT 06039

Curriculum Vitae